Clinical Trial

Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The aim of this study is to demonstrate that in subjects with moderate to severe chronic graft-versus-host disease in the third line and beyond, the use of rosuvastatin compared to the protocol chosen by the researchers can significantly improve the objective response rate of subjects at week 24.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-11-08; most recent amendment 2025-12-05.
Status change: Not Yet Recruiting → Recruiting 2024-11-25
Trial Details
NCT Number NCT06682169
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions Graft-versus-host Disease
Enrollment 182 participants
Start Date 2024-11-20
Primary Completion 2029-10 (estimated)
Study Completion 2030-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-08